Homology Medicines Inc expected to post a loss of 47 cents a share - Earnings Preview

Q32 Bio

11/08/2023 12:24

* Homology Medicines Inc  FIXX.OQ   FIXX.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 14
(estimated). 
    * The Bedford Massachusetts-based  company is expected to
report 
a 4.9% increase in revenue to $841.33 thousand from $802
thousand a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Homology Medicines
Inc is
for a loss of 47 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Homology
Medicines Inc is $2​, above​ its last closing price of $1.19.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.54       -0.53      -0.50     Beat    5.7
 Dec. 31 2023  -0.51       -0.50      -0.60     Missed  -19.1
 Sep. 30 2022  -0.48       -0.47      -0.59     Missed  -24.9​
 Jun. 30 2022  -0.56       -0.56      -0.51     Beat    8.2
 ​​Mar.        -0.25       -0.35      -0.20     Beat    42.9
 31 2022                                                
 Dec. 31 2021  -0.59       -0.59      -0.59     Met     0.4​
 Sep. 30 2021  -0.58       -0.60      -0.54     Beat    10
 Jun. 30 2021  -0.62       -0.59      -0.54     Beat    8.8
 This summary was machine generated August 11 at 11:24 GMT.  All
figures in US dollars  unless otherwise stated